mRNA-1273 Induces Stronger Response Than BNT162b2 for Immunosuppressed
Findings seen in immunosuppressed patients with rheumatic and musculoskeletal diseases, solid organ transplant recipients
Findings seen in immunosuppressed patients with rheumatic and musculoskeletal diseases, solid organ transplant recipients
In large cohort, there were 5.55 excess events per 100,000 vaccinees after BNT162b2 and 18.39 after mRNA-1273
Real-world evidence suggests that kidney transplant recipients who receive 2 doses of a SARS-CoV-2 mRNA vaccine are at lower risk for infection with the COVID-19 virus.
Difference in absolute risk for three versus four doses was 180.1 and 68.8 cases per 100,000 for COVID-19-related hospitalization, severe COVID-19
Strategies, such as booster doses, appear warranted in this population.
Researchers determined risk for gout flares and the effect of colchicine prophylaxis on flares following COVID-19 vaccination.
CoVac-1, a peptide vaccine, induces T-cell immune responses in those with B-cell deficiencies, particularly leukemia and lymphoma patients
Compared with the general population, recipients of solid organ transplants have had a higher risk of breakthrough COVID-19 infection, hospitalization, and death.
The COVID-19 pandemic has underscored how easy it is for disreputable and non-authoritative sources to spread wrong and possibly dangerous medical information.
Echoing the FDA, the CDC also supported a second booster for ‘certain immune-compromised individuals’